Adult Immune Thrombocytopenia Purpura

Adult Immune Thrombocytopenia Purpura

Episodes

Specialty:

All

Year:

All

EP. 1: ITP Pathogenesis, Presentation, and Diagnostic Workup

January 24th 2019

EP. 2: ITP Treatment Selection Criteria and Treatment Goals

January 24th 2019

EP. 3: ITP Patient Management and Important Treatment Factors

January 24th 2019

EP. 4: First-Line Therapy Options for Patients with ITP

January 24th 2019

EP. 5: Steroid Combination Therapy & New ASH Guidelines

January 24th 2019

EP. 6: Second-Line Treatment Options for Patients with ITP

January 24th 2019

EP. 7: Fostamatinib as Second-Line ITP Therapy

January 24th 2019

EP. 8: Romiplostim Classification and Mechanism of Action

January 24th 2019

EP. 9: TPO Receptor Agonist Selection and Patient Adherence

January 24th 2019

EP. 10: TPO Duration of Response and Toxicity

January 24th 2019

EP. 11: Rituximab and Salvage Therapies for Patients With ITP

January 24th 2019

EP. 12: The Future of ITP Treatment

January 24th 2019

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

The OncFive: Top Oncology Articles for the Week of 8/30

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

August Roundup of FDA Approvals in Oncology: Daraxonrasib Highlights 5 Decisions to Know